 |
|
|
|
|
|
|
|
 |
|
||||||
 |
 |
 |
 |
 |
 |
 |
|
Analyst Conference Summaries
Opexa Therapeutics
OPXA
conference date: August 11, 2016 @ 1:30 PM Pacific Time
Note: Opexa announced that its Abili-T trial failed its primary endpoints on October 28, 2016. I sold my stock afterwards, lost some money, but then I had just a few shares in case the trial had positive results. I will no longer cover Opexa, even though it has another therapy in development.
2016 |
|||
05/12/2016 |
08/11/2016 |
||
2015 |
|||
05/12/2015 |
08/12/2015 |
11/10/2015 |
03/15/2016 |
Opexa Therapeutics (OPXA) is a discovery-stage biotechnology company specializing in immunotherapies, with its most advanced therapy targetting multiple sclerosis.
Opexa Therapeutics web site
OPXA investor relations page
More Analyst Conference Pages:
| AGEN |
| AGIO |
| ALNY |
| ALXN |
| AMAT |
| AMD |
| AMGN |
| BIIB |
| BIND |
| CLDX |
| CELG |
| EPZM |
| GILD |
| GLYC |
| HNSN |
| INO |
| INTC |
| ISRG |
| JUNO |
| MACK |
| MCHP |
| MDVN |
| MYL. |
| NVDA |
| OPXA |
| PLX |
| REGN |
| SGEN |
| XLNX |
| XLRN |
Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. This is investment journalism, not financial advice.
Copyright 2015 William P. Meyers